Evaluating bevacizumab with pembrolizumab & chemotherapy in cervical cancer

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, discusses real-world outcomes of adding bevacizumab to pembrolizumab and chemotherapy in patients with advanced cervical cancer. Patients receiving carboplatin-based regimens plus bevacizumab experienced improved overall survival compared to those without, while trends toward benefit were also noted in cisplatin-based cohorts. Addition of bevacizumab did not increase rates of serious adverse events such as fistulae, bowel perforation, or pulmonary embolism, supporting its potential utility in this setting. This interview took place at 2025 European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next